
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number 001-38452

MEREO BIOPHARMA GROUP PLC

(Exact name of Registrant as specified in its charter)

England and Wales

Not Applicable

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

One Cavendish Place, 4th Floor

London, W1G 0QF

United Kingdom

+44-333-023-7300

(Address of principal executive offices)

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing five ordinary shares, nominal value of £0.003 per share	MREO	The Nasdaq Stock Market LLC
Ordinary Shares, nominal value of £0.003 per share		The Nasdaq Stock Market LLC*

* Not for trading, but only in connection with the registration of American Depositary Shares representing such Ordinary Shares pursuant to the requirements of the U.S. Securities and Exchange Commission.

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

As of November 7, 2025 the number of outstanding ordinary shares, par value £0.003 per share, of the registrant was 795,658,504.

Table of Contents

	Page
PART I	
Item 1. Financial Statements	2
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3. Quantitative and Qualitative Disclosures About Market Risk	27
Item 4. Controls and Procedures	28
PART II	
Item 1. Legal Proceedings	29
Item 1A. Risk Factors	29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3. Defaults Upon Senior Securities	29
Item 4. Mine Safety Disclosures	29
Item 5. Other Information	29
Item 6. Exhibits	30
Signatures	31

GENERAL INFORMATION

In this Quarterly Report on Form 10-Q (“Quarterly Report”), “Mereo,” the “Group,” the “Company,” “we,” “us” and “our” refer to Mereo BioPharma Group plc and its consolidated subsidiaries, except where the context otherwise requires.

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” or the negative of these words or other comparable terminology.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. Risk Factors of our most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 26, 2025 (the “2024 Annual Report”). Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

MEREO BIOPHARMA GROUP PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 48,698	\$ 69,802
Prepaid expenses and other current assets	2,694	2,175
Research and development incentives receivables	1,015	2,786
Total current assets	52,407	74,763
Property and equipment, net	174	257
Operating lease right-of-use assets, net	378	727
Intangible assets, net	643	643
Total assets	\$ 53,602	\$ 76,390
Liabilities		
Current liabilities:		
Accounts payable	\$ 879	\$ 2,440
Accrued expenses	4,118	4,071
Convertible loan notes – current	—	5,535
Operating lease liabilities – current	397	707
Other current liabilities	622	1,095
Total current liabilities	6,016	13,848
Warrant liabilities – non-current	336	821
Operating lease liabilities – non-current	—	187
Other non-current liabilities	652	565
Total liabilities	\$ 7,004	\$ 15,421
Commitments and contingencies (Note 16)		
Shareholders' Equity		
Ordinary shares, par value £0.003 per share; 795,484,404 shares issued at September 30, 2025 (December 31, 2024: 775,728,034)	\$ 3,134	\$ 3,059
Additional paid-in capital	548,041	539,642
Accumulated deficit	(493,667)	(462,883)
Accumulated other comprehensive loss	(10,910)	(18,849)
Total shareholders' equity	46,598	60,969
Total liabilities and shareholders' equity	\$ 53,602	\$ 76,390

The accompanying notes form an integral part of these condensed consolidated financial statements.

MEREO BIOPHARMA GROUP PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenue	\$ —	\$ —	\$ 500	\$ —
Operating expenses				
Cost of revenue	—	—	(133)	—
Research and development	(4,270)	(3,170)	(13,573)	(12,109)
General and administrative	(6,045)	(6,203)	(18,811)	(19,980)
Other income	300	—	300	—
Loss from operations	(10,015)	(9,373)	(31,717)	(32,089)
Other income/(expenses)				
Interest income	504	983	1,752	2,160
Interest expense	(28)	(353)	(232)	(995)
Changes in the fair value of warrants	196	(59)	511	(576)
Foreign currency transaction gain/(loss), net	1,873	(6,425)	(6,218)	(5,780)
Benefit from research and development tax credit	446	226	1,377	1,073
Net loss before income tax	(7,024)	(15,001)	(34,527)	(36,207)
Income tax benefit	—	—	—	—
Net loss	<u>\$ (7,024)</u>	<u>\$ (15,001)</u>	<u>\$ (34,527)</u>	<u>\$ (36,207)</u>
Loss per share – basic and diluted	\$ (0.01)	\$ (0.02)	\$ (0.04)	\$ (0.05)
Weighted average shares outstanding – basic and diluted	799,947,013	770,146,589	796,018,903	727,808,860
Net loss	\$ (7,024)	\$ (15,001)	\$ (34,527)	\$ (36,207)
Other comprehensive (loss)/income – Foreign currency translation adjustments, net of tax	(2,267)	7,174	7,939	6,381
Total comprehensive loss	<u>\$ (9,291)</u>	<u>\$ (7,827)</u>	<u>\$ (26,588)</u>	<u>\$ (29,826)</u>

The accompanying notes form an integral part of these condensed consolidated financial statements.

MERO BIOPHARMA GROUP PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

	Nine Months Ended September 30,	
	2025	2024
Cash flows from operating activities		
Net loss	\$ (34,527)	\$ (36,207)
Adjustments to reconcile net loss to net cash used in operating activities:		
Share-based compensation	6,055	5,875
Depreciation	121	105
Amortization of intangible assets	41	328
Amortization of operating lease right-of-use assets	395	381
Change in fair value of warrants	(511)	576
Interest income	(34)	—
Non-cash interest expense	210	974
Foreign currency transaction loss	6,218	5,780
Other income	(300)	—
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	(319)	1,514
Research and development incentives receivable	1,869	(1,073)
Accounts payable	(1,825)	(697)
Accrued expenses and other liabilities	(133)	(486)
Operating lease liabilities	(549)	(484)
Net cash used in operating activities	(23,289)	(23,414)
Cash flows from investing activities		
Payments for intangible assets	(300)	(699)
Purchase of property and equipment	(20)	—
Proceeds from out-licensing	300	—
Net cash used in investing activities	(20)	(699)
Cash flows from financing activities		
Proceeds from exercise of warrants	487	—
Proceeds from issuance of ordinary shares	—	47,000
Transaction costs on issuance of ordinary shares	(199)	(813)
Net cash provided by financing activities	288	46,187
(Decrease)/increase in cash and cash equivalents	(23,021)	22,074
Cash and cash equivalents at January 1,	69,802	57,421
Effect of exchange rate changes	1,917	1,027
Cash and cash equivalents at September 30,	\$ 48,698	\$ 80,522
Supplemental disclosure		
Cash paid for interest	22	10

The accompanying notes form an integral part of these condensed consolidated financial statements.

MEREO BIOPHARMA GROUP PLC
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In thousands, except share amounts)
(Unaudited)

	Ordinary shares		Treasury shares		Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total shareholders' equity
	Shares	Par value	Shares	Par value				
Balance, December 31, 2024	775,728,034	\$ 3,059	—	\$ —	\$ 539,642	\$ (18,849)	\$ (462,883)	\$ 60,969
Net loss	—	—	—	—	—	—	(12,887)	(12,887)
Foreign currency translation adjustments	—	—	—	—	—	3,559	—	3,559
Share-based compensation	—	—	—	—	2,278	—	—	2,278
Delivery of shares on vesting of restricted stock units	718,350	3	—	—	(3)	—	—	—
Transaction costs on issuance of shares	—	—	—	—	(65)	—	—	(65)
Conversion of convertible loan notes	17,105,450	64	—	—	5,676	—	—	5,740
Exercise of warrants	1,449,610	6	—	—	481	—	—	487
Transfer between reserves	—	—	—	—	(3,743)	—	3,743	—
Balance, March 31, 2025	795,001,444	\$ 3,132	—	\$ —	\$ 544,266	\$ (15,290)	\$ (472,027)	\$ 60,081
Net loss	—	—	—	—	—	—	(14,616)	(14,616)
Foreign currency translation adjustments	—	—	—	—	—	6,647	—	6,647
Share-based compensation	—	—	—	—	2,065	—	—	2,065
Balance, June 30, 2025	795,001,444	\$ 3,132	—	\$ —	\$ 546,331	\$ (8,643)	\$ (486,643)	\$ 54,177
Net loss	—	—	—	—	—	—	(7,024)	(7,024)
Foreign currency translation adjustments	—	—	—	—	—	(2,267)	—	(2,267)
Share-based compensation	—	—	—	—	1,712	—	—	1,712
Delivery of shares on vesting of restricted stock units	482,960	2	—	—	(2)	—	—	—
Balance, September 30, 2025	795,484,404	\$ 3,134	—	\$ —	\$ 548,041	\$ (10,910)	\$ (493,667)	\$ 46,598
Balance, December 31, 2023	701,217,089	\$ 2,775	923,400	\$ (1,230)	\$ 486,107	\$ (17,485)	\$ (419,630)	\$ 50,537
Net loss	—	—	—	—	—	—	(8,951)	(8,951)
Foreign currency translation adjustments	—	—	—	—	—	(798)	—	(798)
Share-based compensation	—	—	—	—	2,050	—	—	2,050
Exercise of share options	132,345	—	(210,485)	280	(280)	—	—	—
Delivery of shares on vesting of restricted stock units	—	—	(712,915)	950	(950)	—	—	—
Balance, March 31, 2024	701,349,434	\$ 2,775	—	\$ —	\$ 486,927	\$ (18,283)	\$ (428,581)	\$ 42,838
Net loss	—	—	—	—	—	—	(12,255)	(12,255)
Foreign currency translation adjustments	—	—	—	—	—	5	—	5
Share-based compensation	—	—	—	—	2,088	—	—	2,088
Exercise of share options	800,890	4	—	—	(6)	—	—	(2)
Delivery of shares on vesting of performance based restricted stock units	4,014,450	15	—	—	(40)	—	—	(25)
Issuance of shares, net of discount	62,656,500	238	—	—	46,762	—	—	47,000
Transaction costs on issuance of shares	—	—	—	—	(999)	—	—	(999)
Balance, June 30, 2024	768,821,274	\$ 3,032	—	\$ —	\$ 534,732	\$ (18,278)	\$ (440,836)	\$ 78,650
Net loss	—	—	—	—	—	—	(15,001)	(15,001)
Foreign currency translation adjustments	—	—	—	—	—	7,174	—	7,174
Share-based compensation	—	—	—	—	1,737	—	—	1,737
Exercise of share options	1,740,840	7	—	—	(13)	—	—	(6)
Delivery of shares on vesting of restricted stock units	433,880	2	—	—	(3)	—	—	(1)
Delivery of shares on vesting of performance based restricted stock units	2,676,305	10	—	—	(27)	—	—	(17)
Balance, September 30, 2024	773,672,299	\$ 3,051	—	\$ —	\$ 536,426	\$ (11,104)	\$ (455,837)	\$ 72,536

The accompanying notes form an integral part of these condensed consolidated financial statements.

MEREO BIOPHARMA GROUP PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Nature of business

Mereo BioPharma Group plc (the “Company” or “Mereo”) is a United Kingdom (“U.K.”) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (“OI”) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (“AATD-LD”).

The Company is a public limited company incorporated and domiciled in the U.K., and registered in England, with shares publicly traded on the Nasdaq Capital Market via American Depositary Shares (“ADSs”) under the ticker symbol “MREO”. The Company’s registered office is located at 4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom.

2. Basis of presentation and summary of significant accounting policies

Basis of presentation

The condensed consolidated financial statements of the Company and its subsidiaries and other financial information included in this quarterly report on Form 10-Q (“Quarterly Report”) are unaudited, have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All intercompany balances and transactions between the Company and its subsidiaries have been eliminated on consolidation.

The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2025 (the “2024 Annual Report”). The condensed consolidated balance sheet as of December 31, 2024 was derived from audited consolidated financial statements included in the 2024 Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments which are, in the opinion of management, necessary to fairly state the Company’s financial position as of September 30, 2025, the results of operations for the three and nine months ended September 30, 2025 and 2024 and cash flows for the nine months ended September 30, 2025 and 2024. The interim results are not necessarily indicative of results to be expected for the full year.

Going concern

The Company has prepared its condensed consolidated financial statements on the basis that it will continue as a going concern. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of delays in initiating or continuing research programs and clinical trials, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, if approved, dependence on key personnel and collaboration partners, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including pre-clinical and clinical testing and regulatory approval prior to commercialization. Even if the Company’s research and development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The Company has historically been loss making, anticipates that it will continue to incur losses for the foreseeable future, and had an accumulated deficit of \$493.7 million as of September 30, 2025. The Company has funded these losses through a combination of public equity financings, private equity and debt financings and various license and collaboration agreements, and it expects it will continue to do so until such time as it can generate significant revenue from product sales, or other commercial revenues, if ever, or through licensing and/or collaboration agreements for its rare disease or other product candidates. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

As of September 30, 2025, the Company had cash and cash equivalents of \$48.7 million. The Company expects that its cash and cash equivalents as of September 30, 2025 will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the date of filing of this Quarterly Report.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting periods. There are no estimates and assumptions made in the condensed consolidated financial statements that are considered to be critical. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

3. Recent accounting pronouncements

There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance other than those previously included in the 2024 Annual Report that are of significance or potential significance to the Company. The Company is continuing to evaluate the impact of the recently issued pronouncements that are effective in future periods and were discussed in its 2024 Annual Report.

4. Fair value measurement

The Company's financial instruments consist of cash and cash equivalents, accounts payable, accrued expenses, deferred consideration, warrant liabilities and the liability component of the convertible loan notes and other financing arrangements. Cash, cash equivalents (except for investments in money market funds), accounts payable and accrued expenses are initially recorded and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.

The following table summarizes the Company's financial assets and liabilities measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy:

	As of September 30, 2025			
	Total (\$'000)	Level 1 (\$'000)	Level 2 (\$'000)	Level 3 (\$'000)
Financial assets				
Cash equivalents (investments in money market funds)	10,987	—	10,987	—
Financial liabilities				
Warrant liabilities	336	—	336	—
	As of December 31, 2024			
	Total (\$'000)	Level 1 (\$'000)	Level 2 (\$'000)	Level 3 (\$'000)
Financial liabilities				
Warrant liabilities	821	—	821	—

Fair values of the investments in money market funds are determined based on the net asset value per share of each fund stated in the fund manager's statement. There were no transfers of instruments between any levels of the fair value hierarchy during the three and nine months ended September 30, 2025 and 2024.

Warrant liabilities

At September 30, 2025 and December 31, 2024, warrant liabilities solely related to those warrants outstanding to the former lenders of the Company as described in Note 11.

5. Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following:

	September 30,	December 31,
	2025	2024
	(\$'000)	(\$'000)
VAT receivable	\$ 520	\$ 464
Prepaid research and development expenses	181	201
Security deposits	394	378
Prepaid insurance premiums	1,261	1,003
Prepaid general and administrative expenses	338	129
Total	<u>\$ 2,694</u>	<u>\$ 2,175</u>

6. Property and equipment, net

Property and equipment, net consists of the following:

	September 30,	December 31,
	2025	2024
	(\$'000)	(\$'000)
Leasehold improvements	\$ 763	\$ 712
Office equipment	210	196
IT equipment	248	298
Property and equipment, at cost	1,221	1,206
Less: accumulated depreciation	(1,047)	(949)
Property and equipment, net	<u>\$ 174</u>	<u>\$ 257</u>

Depreciation expense was less than \$0.1 million for both the three months ended September 30, 2025 and 2024 and \$0.1 million for both the nine months ended September 30, 2025 and 2024.

7. Leases

In August 2015, the Company entered into a lease agreement under which it leased office space located on the fourth floor of One Cavendish Place, London, with a lease term ending in August 2025. In June 2021, the Company entered into a new lease agreement to lease additional office space located on the fifth floor of that building for a lease period ending in June 2026. At the same time, the Company entered into a reversionary lease to extend the term for the original fourth floor lease to be coterminous with the fifth floor, ending in June 2026.

The total lease expense included in the statements of operations and comprehensive loss was \$0.2 million and \$0.5 million for the three and nine months ended September 30, 2025, respectively and \$0.2 million and \$0.5 million for the three and nine months ended September 30, 2024, respectively. There were no material variable lease costs.

	As of September 30,	
	2025	2024
Operating leases		
Weighted-average remaining contractual lease term (years)	0.75	1.70
Weighted average discount rate	10.0%	10.0%

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2025	2024	2025	2024
	(\$'000)	(\$'000)	(\$'000)	(\$'000)
Cash paid for amounts included in the measurement of lease liabilities:				
Operating cash flows from operating leases	\$ 203	\$ 198	\$ 605	\$ 585

The following table summarizes the maturities of the Company's operating lease liabilities as of September 30, 2025:

	As of September 30, 2025
	(\$'000)
Maturity analysis of the operating lease liabilities for the years ending December 31,	
2025	\$ 205
2026	205
Total undiscounted payments	410
Less: Present value discount	(13)
Lease liability	\$ 397
Lease liability – current	\$ 397
Lease liability – non-current	\$ —

8. Other current liabilities

Other current liabilities consist of the following:

	September 30,	December 31,
	2025	2024
	(\$'000)	(\$'000)
Social security and other taxes	\$ 211	\$ 503
Deferred consideration liability	286	296
Equity issuance costs payable	94	235
Other current liabilities	31	61
Total	\$ 622	\$ 1,095

9. Accrued expenses

Accrued expenses consist of the following:

	September 30,	December 31,
	2025	2024
	(\$'000)	(\$'000)
Accrued research and development costs	\$ 985	\$ 948
Accrued legal and professional fees	680	727
Accrued bonus	1,874	2,001
Accrued local taxes	280	267
Other accrued expenses	299	128
Total	\$ 4,118	\$ 4,071

10. Convertible loan notes and equity classified warrants

Novartis Loan Note

On February 10, 2020, the Company entered into a convertible equity financing with Novartis Pharma (AG) ("Novartis"), which it amended in February 2023 to extend the maturity date and increase the interest rate, under which Novartis purchased a £3.8 million (\$5.0 million) convertible loan note (the "Novartis Loan Note"). Following the 2023 amendment, the Novartis Loan Note was convertible at the discretion of the holder, at a fixed price of £0.265 per ordinary share and bore interest at 9% per annum with a maturity date of February 10, 2025.

On February 7, 2025, the Company received a conversion notice and subsequently issued and allotted 17,105,450 ordinary shares (equivalent to 3,421,090 ADSs) on the non-cash conversion of the outstanding principal and accrued interest of the Novartis Loan Note.

As of December 31, 2024, the net carrying amount of the liability component of the convertible debt instrument was \$5.5 million. On conversion, the Company derecognized the carrying value of the Novartis Loan Note of \$5.7 million and recognized the issuance of the shares at their par value within ordinary share capital and the excess amount of the conversion price over the par value within additional paid-in capital. In addition, the amount that represented the value of the conversion features of the Novartis Loan Note presented in additional paid-in capital at inception of \$3.4 million was transferred to accumulated deficit upon conversion.

The Company recognized no interest expense in relation to the Novartis Loan Note for the three months ended September 30, 2025, and \$0.2 million for the nine months ended September 30, 2025, and \$0.3 million and \$0.9 million for the three and nine months ended September 30, 2024, respectively. The effective interest rate applied to the liability portion of the Novartis Loan Note for the nine months ended September 30, 2025 and the three and nine months ended September 30, 2024 was 27.8%.

Equity classified warrants

In connection with the Novartis Loan Note, the Company also issued warrants over 1,449,610 ordinary shares to Novartis which were exercisable until February 2025 at an exercise price of £0.265 per ordinary share (the "2020 Novartis Warrants"). In connection with the amendments to the Novartis Loan Note, in February 2023 the Company issued warrants over a further 2,000,000 ordinary shares (the "2023 Novartis Warrants"). The 2023 Novartis Warrants are exercisable until February 2028 at an exercise price of £0.15 per ordinary share. Both tranches of warrants were recognized separately as equity instruments.

On February 7, 2025, Novartis exercised the 2020 Novartis Warrants and the Company subsequently issued and allotted 1,449,610 ordinary shares (equivalent to 289,922 ADSs) upon receipt of \$0.5 million in satisfaction of the subscription price of £0.265 per ordinary share. Additional paid-in capital of \$0.3 million, representing the surplus of previously recognized amounts exceeding the par value of ordinary shares, was transferred to accumulated deficit.

11. Warrant liability

	Warrant liabilities	
	2025	2024
	(\$'000)	(\$'000)
At January 1	\$ 821	\$ 412
Changes in fair value during the period	(416)	448
Foreign exchange	14	(5)
At March 31	\$ 419	\$ 855
Changes in fair value during the period	101	69
Foreign exchange	25	1
At June 30	\$ 545	\$ 925
Changes in fair value during the period	(196)	59
Foreign exchange	(13)	56
At September 30	\$ 336	\$ 1,040

As of September 30, 2025, the former lenders of the Company have warrants outstanding to purchase a total of 1,243,908 ordinary shares at an exercise price of £2.95 per share, exercisable until August 2027 and a total of 1,243,908 ordinary shares at an exercise price of \$0.4144 per share, exercisable until dates between August 2027 and October 2028. These warrants outstanding are equivalent to 0.3% of the issued ordinary share capital of the Company as of September 30, 2025 and 0.3% as of December 31, 2024. There were no warrants classified as liabilities exercised during the three and nine months ended September 30, 2025 and 2024.

The fair value of each warrant is estimated using the Black-Scholes option pricing model using the following weighted average assumptions:

	<u>September 30,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Market value of ADSs (\$)	\$ 2.06	\$ 3.50
Risk-free interest rate (%)	4.04%	4.15%
Expected life (years)	2.0	2.8
Expected volatility (%)	101.79%	95.00%
Expected dividends (%)	0.00%	0.00%

12. Shareholders' Equity

Ordinary Shares

	<u>Number of</u> <u>ordinary shares</u>	<u>Par value</u> <u>(\$'000)</u>
At January 1, 2024	701,217,089	\$ 2,775
Exercise of share options	132,345	—
At March 31, 2024	701,349,434	\$ 2,775
Exercise of share options	800,890	4
Vesting of RSUs	4,014,450	15
Issuance of ordinary shares	62,656,500	238
At June 30, 2024	768,821,274	\$ 3,032
Exercise of share options	1,740,840	7
Vesting of RSUs	433,880	2
Vesting of PSUs	2,676,305	10
At September 30, 2024	773,672,299	\$ 3,051
At January 1, 2025	775,728,034	\$ 3,059
Vesting of RSUs	718,350	3
Conversion of convertible loan notes	17,105,450	64
Exercise of warrants	1,449,610	6
At March 31 and June 30, 2025	795,001,444	\$ 3,132
Vesting of RSUs	482,960	2
At September 30, 2025	795,484,404	\$ 3,134

In February 2025, the Company issued and allotted 17,105,450 ordinary shares (equivalent to 3,421,090 ADSs) on the non-cash conversion of the outstanding principal and accrued interest of the Novartis Loan Note.

In February 2025, the Company issued and allotted 1,449,610 ordinary shares (equivalent to 289,922 ADSs) upon exercise of the 2020 Novartis Warrants.

During the three and nine months ended September 30, 2025, 482,960 and 1,201,310 ordinary shares were issued due to the vesting of RSUs, respectively.

13. Revenue and cost of revenue

ReproNovo Partnership

In December 2023, the Company and ReproNovo SA. (“ReproNovo”) entered into a global licensing agreement for the development and commercialization of leflutrozone (the “ReproNovo Licensing Agreement”). Under the terms of the ReproNovo Licensing Agreement, ReproNovo received an exclusive worldwide license to develop and commercialize leflutrozone.

The Company recognized a milestone payment of \$0.5 million as revenue in the three months ended June 30, 2025 following confirmation by ReproNovo that the first participant had been included in a Phase 2 trial of leflutrozone. No revenues were recognized during the three months ended September 30, 2025 or either the three and nine months ended September 30, 2024.

As a consequence of the milestone payment becoming receivable, the Company recognized \$0.1 million as cost of revenue in the three months ended June 30, 2025 in accordance with the terms of the 2015 asset purchase agreement with Novartis. No cost of revenue was recognized during the three months ended September 30, 2025 or either the three and nine months ended September 30, 2024.

14. Share based compensation

The Company currently grants equity awards under the Mereo 2019 Equity Incentive Plan (the “2019 EIP”) and the 2019 Non-Employee Equity Incentive Plan (the “2019 NED EIP”). There are also still outstanding awards under two previous plans, the Mereo BioPharma Group Limited Share Option Plan and the Mereo Share Option Plan (together the “Previous Share Option Plans”), however no further grants are envisioned from these plans.

The total number of ADSs available for issue under the 2019 EIP and 2019 NED EIP was 14.2 million as of September 30, 2025.

The expense for share-based compensation arises solely in respect of awards made under these two active plans as follows:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2025	2024	2025	2024
	(\$'000)	(\$'000)	(\$'000)	(\$'000)
2019 EIP	\$ 1,453	\$ 1,470	\$ 4,667	\$ 4,498
2019 NED EIP	259	266	1,388	1,377
Total	\$ 1,712	\$ 1,736	\$ 6,055	\$ 5,875

As of September 30, 2025, the total unrecognized compensation cost related to outstanding share awards was \$5.7 million, which the Company expects to recognize over a weighted-average period of 1.6 years.

2019 EIP

The Company has awarded the following instruments under the 2019 EIP:

Market Value Options (“Options”)

A summary of the Company’s Options activity and related information under the 2019 EIP for the nine months ended September 30, 2025 is as follows; all outstanding Options are expected to vest:

	Number of options (ADSs)	Weighted Average Exercise Price (\$)	Aggregate intrinsic value (\$'000)
At December 31, 2024	11,271,023	\$ 2.02	\$ 15,578
Granted	2,394,090	2.89	—
Forfeited	(133,506)	2.41	—
At September 30, 2025	13,531,607	\$ 2.17	\$ 4,839
Vested	8,120,615	\$ 1.97	\$ 3,444

The weighted average fair value per share of Options granted during the nine months ended September 30, 2025 and 2024 was \$2.41 and \$2.61, respectively.

The weighted average contractual life of Options outstanding as of September 30, 2025 and December 31, 2024 was 7.2 years and 7.6 years, respectively. The weighted average contractual life for vested Options as of September 30, 2025 and December 31, 2024 was 6.4 years and 6.8 years, respectively.

Where presented, the aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company's ADSs for the Options that were in-the-money.

The fair value of each Option is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

	Nine Months Ended September 30,	
	2025	2024
Risk-free interest rate (%)	4.48%	4.02%
Expected life (years)	6.25	6.25
Expected volatility (%)	104.28%	90.81%
Expected dividends (%)	0.00%	0.00%

Expected volatility is calculated by reference to the historical volatility of the Company's ADSs for the nine months ended September 30, 2025 and an appropriate peer group of companies for the nine months ended September 30, 2024. The grant date fair value is recognized over the requisite service period using the accelerated graded-vesting attribution method.

Restricted Stock Units ("RSUs")

A summary of the Company's RSU activity and related information under the 2019 EIP for the nine months ended September 30, 2025 is as follows; all outstanding RSUs are unvested and expected to vest:

	Number of RSUs (ADSs)	Weighted Average Grant Date Fair Value (\$)
At December 31, 2024	441,247	\$ 2.10
Granted	290,794	2.83
Vested	(240,262)	1.98
Forfeited	(69,912)	2.39
At September 30, 2025	421,867	\$ 2.62

At September 30, 2025, the weighted average remaining vesting period of RSUs outstanding was 2.1 years. The total fair value of RSUs vested and delivered during the nine months ended September 30, 2025 and 2024 was \$0.6 million and \$0.8 million, respectively.

The fair value of each RSU was calculated by reference to the value of the shares awarded. The grant date fair value is recognized over the vesting period using the accelerated graded-vesting attribution method.

2019 NED EIP

The Company has awarded the following instruments under the 2019 NED EIP:

Options

A summary of the Company's Options activity and related information under the 2019 NED EIP for the nine months ended September 30, 2025 is as follows; all outstanding Options are expected to vest:

	Number of options (ADSs)	Weighted Average Exercise Price (\$)	Aggregate intrinsic value (\$'000)
At December 31, 2024	1,542,087	\$ 2.16	\$ 2,123
Granted	440,000	3.16	—
At September 30, 2025	1,982,087	\$ 2.38	\$ 704
Vested	1,798,759	\$ 2.31	\$ 704

The weighted average fair value per share of Options granted during the nine months ended September 30, 2025 and 2024 was \$2.51 and \$2.83, respectively.

The weighted average contractual life of Options outstanding as of September 30, 2025 and December 31, 2024 was 7.1 years and 7.5 years, respectively. The weighted average contractual life for vested Options as of September 30, 2025 and December 31, 2024 was 7.1 years and 7.4 years, respectively.

Where presented, the aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company's ADSs for the Options that were in-the-money.

The fair value of each Option is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions:

	Nine Months Ended September 30,	
	2025	2024
Risk-free interest rate (%)	4.25%	4.08%
Expected life (years)	5.25	5.25
Expected volatility (%)	104.31%	90.67%
Expected dividends (%)	0.00%	0.00%

Expected volatility is calculated by reference to the historical volatility of the Company's ADSs for the nine months ended September 30, 2025 and an appropriate peer group of companies for the nine months ended September 30, 2024. The grant date fair value is recognized over the vesting period using the accelerated graded-vesting attribution method.

Deferred Restricted Stock Units ("DRSUs")

A summary of the Company's DRSUs activity and related information under the 2019 NED EIP for the nine months ended September 30, 2025 is as follows; all outstanding DRSUs are expected to vest:

	Number of DRSUs (ADSs)	Weighted Average Grant Date Fair Value (\$)
At December 31, 2024	855,375	\$ 1.43
Granted	124,233	3.16
At September 30, 2025	979,608	\$ 1.65
Vested	938,198	\$ 1.58
Unvested	41,410	3.16

As of December 31, 2024, there were 20,903 DRSUs unvested with a weighted average grant date fair value of \$3.87 per DRSU. The total fair value of DRSUs vested during the nine months ended September 30, 2025 and 2024 was \$0.3 million and \$0.4 million, respectively.

The fair value of each DRSU was calculated by reference to the value of the shares awarded. The grant date fair value is recognized over the vesting period using the accelerated graded-vesting attribution method.

Previous Share Option Plans

Mereo previously granted Options to employees under the Previous Share Options Plans. No awards have been granted under either of these plans following the introduction of the 2019 EIP and the 2019 NED EIP and no further awards are envisioned.

A summary of the Company's Options activity and related information under the Previous Share Options Plans for the nine months ended September 30, 2025 is as follows; all outstanding Options are vested:

	Number of options (ADSs)	Weighted Average Exercise Price (\$)	Aggregate intrinsic value (\$'000)
At December 31, 2024	1,419,867	\$ 9.24	\$ —
Expired	(1,231,011)	8.63	—
At September 30, 2025	188,856	\$ 13.22	\$ —

The weighted average contractual life of Options outstanding and vested at September 30, 2025 and December 31, 2024 was 0.8 years and 0.8 years, respectively.

15. Loss per share

Basic loss per share is calculated by dividing the loss attributable to ordinary equity holders of the Company for the period by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based on dividing the loss attributable for the period, adjusted for the effect of dilutive ordinary shares, by ordinary share equivalents, which includes the weighted average number of ordinary shares outstanding and the effect of dilutive ordinary share equivalents.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
	(\$'000, except share and per share amounts)	(\$'000, except share and per share amounts)	(\$'000, except share and per share amounts)	(\$'000, except share and per share amounts)
Net loss	\$ (7,024)	\$ (15,001)	\$ (34,527)	\$ (36,207)
Net loss per share - basic and diluted	\$ (0.01)	\$ (0.02)	\$ (0.04)	\$ (0.05)
Weighted-average number of shares used in computing loss per share - basic and diluted	799,947,013	770,146,589	796,018,903	727,808,860

The Company's potentially dilutive securities in the table below have been excluded from the computation of diluted loss per share as the effect for the three and nine months ended September 30, 2025 and 2024 would be to reduce the loss per share. Therefore, the weighted average number of ordinary shares outstanding used to calculate both basic and diluted loss per share is the same.

	Nine Months Ended September 30,	
	2025	2024
Ordinary shares issuable for:		
Share-based compensation awards	80,829,135	77,646,275
Convertible loan notes	—	16,637,208
Warrant liabilities	2,487,816	2,487,816
Warrants classified in equity	3,551,699	5,051,313

16. Commitments and contingencies

Indemnification agreements

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. In accordance with the Articles of Association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.

Novartis Asset Purchase Agreements

The Company has agreed to make future payments to Novartis comprising amounts equal to ascending specified percentages of tiered annual worldwide net sales (beginning at high single digits and reaching into double digits at higher sales) of products that include the assets acquired. The levels of ascending percentages of tiered annual worldwide net sales are stipulated under the respective Purchase Agreements.

The Company further agreed that in the event it transfers, licenses, assigns or leases all or substantially all of its assets, it will pay Novartis a percentage of the proceeds of such transaction. The payment of a percentage of proceeds is not payable with respect to any transaction involving equity interests of Mereo BioPharma Group plc, a merger or consolidation of Mereo BioPharma Group plc, or a sale of any assets of Mereo BioPharma Group plc.

License agreement with AstraZeneca

In October 2017, the Company entered into an exclusive license and option agreement (“the AstraZeneca License Agreement”) and subscription deed (the “AstraZeneca Subscription Deed”), together (the “Original Agreements”) with AstraZeneca AB (“AstraZeneca”). Each of these were amended on November 8, 2024, when the Company entered into an amendment and restatement agreement related to the AstraZeneca License Agreement (the “Amended AstraZeneca License Agreement”) and a Deed of Amendment and Restatement related to the AstraZeneca Subscription Deed (the “Amended AstraZeneca Subscription Deed”) together (the “Amended AstraZeneca Agreements”).

Under the terms of the Original Agreements, the Company obtained from AstraZeneca an exclusive worldwide, sub-licensable license under AstraZeneca’s intellectual property rights relating to alvelestat, with an option to acquire such intellectual property rights following commencement of a pivotal trial and payment of related milestone payments, together with the acquisition of certain related assets. Upon entering into the Original Agreements, the Company made a payment of \$3.0 million and issued 490,798 ordinary shares (equivalent to 98,159 ADSs) to AstraZeneca, for an aggregate upfront payment equal to \$5.0 million. Upon execution of the Amended AstraZeneca License Agreement, the Company issued 2,044,392 ordinary shares and paid \$0.5 million to AstraZeneca in respect of an agreed milestone.

Under the terms of the Amended AstraZeneca Agreements, the Company has agreed, in connection with certain further development and regulatory milestones, to make potential future payments both in cash and through the issue of a variable number of additional ADSs to AstraZeneca of up to \$114.3 million in the aggregate for products included in the Amended AstraZeneca License Agreement.

The number of ADSs to be issued to satisfy each equity milestone is determined by dividing a monetary amount by a defined subscription price based on the weighted average trading price of the Company's ADSs, and the obligation is presented as a liability under ASC Topic 480, Distinguishing Liabilities from Equity. The Company continues to reassess the fair value of such instruments in each reporting period until the milestones are achieved, if ever, and the issuance of shares occurs. Given the pervasive uncertainty involved in establishing the amounts, timing and likelihood of the future cash flows, including the Company’s ability to secure either a partnership or alternative forms of non-dilutive financing, the possible terms and rate of such a partnership or financing, the clinical and regulatory performance of the product candidate and the lack of comparable recent transactions, the Company has determined the fair value of the equity milestones to be paid in a variable number of shares pursuant to its Amended AstraZeneca License Agreement to be negligible and therefore assigned a nil value to the instrument as of September 30, 2025.

In addition to the development and regulatory milestones, the Company has agreed to make payments to AstraZeneca based on specified commercial milestones of the product. The Company has also agreed to pay a specified percentage of sub-licensing revenue to AstraZeneca and to make royalty payments to AstraZeneca equal to ascending specified percentages of tiered annual worldwide net sales by the Company of licensed products (subject to certain reductions), ranging from the high single digits to low double digits. Royalties will be payable on a licensed-product-by-licensed-product and country-by-country basis until the later of ten years after the first commercial sale of such licensed product in such country and expiration of the last patent covering such licensed product in such country that would be sufficient to prevent generic entry. The Company has agreed to use commercially reasonable efforts to develop and commercialize at least one licensed product.

The Amended AstraZeneca License Agreement will expire on the expiration of the last-to-expire royalty term with respect to all licensed products. Upon the expiration of the royalty term for a licensed product in a particular country, the licenses to the Company for such product in such country will become fully paid and irrevocable. Prior to exercise of the Option, if at all, the Company may terminate the Amended AstraZeneca License Agreement upon prior written notice. Either party may terminate the agreement upon prior written notice for the other party’s material breach that remains uncured for a specified period of time or insolvency.

Research and development activities

The Company enters into contracts in the normal course of business with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) and other third parties to assist in the performance of research and development activities and other services and products for operating purposes. The contracts with CROs generally provide for termination on notice, and therefore, are cancellable contracts and not included herein. The Company has manufacturing commitments with CMOs of \$0.1 million and \$0.5 million as of September 30, 2025 and December 31, 2024, respectively.

Manufacturing and supply agreement with Ultragenyx

In December 2024, the Company entered into a manufacturing and supply agreement with Ultragenyx Pharmaceutical Inc. ("Ultragenyx") under which Ultragenyx is responsible for the manufacture and supply of setrusumab to the Company in its territories. The Company is also required to reimburse Ultragenyx for a portion of the manufacturing process development costs as well as future commercial supply costs.

Legal proceedings

From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have any material contingency reserves established for any liabilities as of September 30, 2025 and December 31, 2024.

17. Related party disclosures

In the three and nine months ended September 30, 2025 and 2024, there were no reportable related party transactions.

18. Segment information

The Company has one operating segment focused on the business of developing rare disease therapies. The chief operating decision maker, its Chief Executive Officer, assesses performance for the entity and decides how to allocate resources based on consolidated net loss before income tax, which is reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets.

The chief operating decision maker uses consolidated net loss before income tax and budget-to-actual variances for consolidated net loss before income tax to assess the performance of the operating segment.

The following table presents certain financial data for the Company's reportable segment, including significant segment expenses regularly provided to the chief operating decision maker to assess performance of the Company.

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2025	2024	2025	2024
	(\$'000)	(\$'000)	(\$'000)	(\$'000)
Revenue	\$ —	\$ —	\$ 500	\$ —
Cost of revenue	—	—	(133)	—
Research and development expenses				
Setrusumab (BPS-804/UX143)	(2,295)	(1,441)	(8,225)	(3,798)
Alvelestat (MPH-966)	(1,689)	(1,206)	(4,450)	(6,721)
Etigilimab (MPH-313)	(229)	(410)	(660)	(1,228)
Other	(57)	(113)	(238)	(362)
General and administrative expenses	(6,045)	(6,203)	(18,811)	(19,980)
Other segment items	3,291	(5,628)	(2,510)	(4,118)
Net loss before income tax	\$ (7,024)	\$ (15,001)	\$ (34,527)	\$ (36,207)

The revenue recognized by the Company during the three and nine months ended September 30, 2025 was attributable to its operations in the U.K.

Other segment items consist of interest income, interest expense, change in fair value of warrants, foreign currency transaction gain/(loss), benefit from research and development tax credit and other income. These are disclosed in the condensed consolidated statements of operations and comprehensive loss.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and the audited consolidated financial statements and notes thereto and management's discussion and analysis of financial condition and results of operations for the year ended December 31, 2024, included in our 2024 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the "Risk Factors" section of our 2024 Annual Report, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.

Overview

We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease product candidates are setrusumab for the treatment of OI and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Setrusumab has received orphan designation for OI from the European Commission ("EC") and the U.S. Food and Drug Administration ("FDA"), PRIME designation from the European Medicines Agency ("EMA") and has Breakthrough Therapy designation and rare pediatric disease designation from the FDA. Alvelestat has received orphan designation for AATD from the EC and the FDA, and Fast Track designation for the treatment of AATD-LD from the FDA. We also have an early stage rare disease program, vantiactumab, for the treatment of a second bone disease, autosomal dominant osteopetrosis type 2. The global development of vantiactumab is being funded and led by our partner, āshibio, Inc. ("āshibio"), and we retain the European commercial rights.

Our strategy is to selectively acquire and develop product candidates for rare diseases that have already received significant investment from large pharmaceutical and biotechnology companies and that have substantial pre-clinical, clinical and manufacturing data packages. Since our formation in March 2015, we have successfully executed on this strategy by acquiring six clinical-stage product candidates of which four were in rare diseases and oncology. Four of our six clinical-stage product candidates were acquired from large pharmaceutical companies and two were acquired in our merger with Mereo BioPharma 5, Inc. (formerly OncoMed Pharmaceuticals, Inc.) in 2019. We have successfully completed large, randomized Phase 2 clinical trials for four of our product candidates and the Phase 1b portion of a Phase 1b/2 for a fifth product candidate.

Rare diseases represent an attractive development and, in some cases, commercialization opportunity for us since they typically have high unmet medical need and can utilize regulatory pathways that facilitate acceleration to approval and to the potential market. Development of products for rare diseases involves close collaboration with key opinion leaders and investigators, and close coordination with patient organizations. Rare disease patients are typically treated at a limited number of specialized sites which helps identification of the patient population and enables a small, targeted sales infrastructure to commercialize the products in key markets.

Results of Operations

Comparison of three months ended September 30, 2025 and 2024

The following table sets forth Mereo's results of operations for the three months ended September 30, 2025 and 2024.

	Three months ended September 30,		Change (\$'000)
	2025 (\$'000)	2024 (\$'000)	
Revenue	\$ —	\$ —	\$ —
Operating expenses			
Cost of revenue	—	—	—
Research and development	(4,270)	(3,170)	(1,100)
General and administrative	(6,045)	(6,203)	158
Other income	300	—	300
Loss from operations	(10,015)	(9,373)	(642)
Other income/(expenses)			
Interest income	504	983	(479)
Interest expense	(28)	(353)	325
Changes in the fair value of warrants	196	(59)	255
Foreign currency transaction gain/(loss), net	1,873	(6,425)	8,298
Benefit from research and development tax credit	446	226	220
Net loss before income tax	(7,024)	(15,001)	7,977
Income tax benefit	—	—	—
Net loss	<u>\$ (7,024)</u>	<u>\$ (15,001)</u>	<u>\$ 7,977</u>
Other comprehensive income – Foreign currency translation adjustments, net of tax	(2,267)	7,174	(9,441)
Total comprehensive loss	<u>\$ (9,291)</u>	<u>\$ (7,827)</u>	<u>\$ (1,464)</u>

Research and development expenses (“R&D expenses”)

The following table sets forth our R&D expenses by product development program for the three months ended September 30, 2025 and 2024.

	Three months ended September 30,		Change (\$'000)
	2025 (\$'000)	2024 (\$'000)	
Setrusumab (BPS-804/UX143)	\$ 2,295	\$ 1,441	854
Alvelestat (MPH-966)	1,689	1,206	483
Etigilimab (MPH-313)	229	410	(181)
Other	57	113	(56)
Total R&D expenses	<u>\$ 4,270</u>	<u>\$ 3,170</u>	<u>1,100</u>

Total R&D expenses increased by \$1.1 million, from \$3.2 million in the three months ended September 30, 2024 to \$4.3 million in the three months ended September 30, 2025.

The increase was primarily due to increases of \$0.9 million in R&D expenses for setrusumab and \$0.5 million for alvelestat, partially offset by a reduction of \$0.2 million in R&D expenses for etigilimab.

The increase in program expenses for setrusumab was primarily driven by amounts due under the manufacturing and supply agreement with our partner, Ultragenyx, as well as ongoing activities related to real-world evidence programs and medical affairs activities in Europe. This is in addition to costs we incur in relation to our collaboration with Ultragenyx, who fund the global development of the program, including input into development, regulatory and manufacturing plans.

The increase in program expenses for alvelestat was primarily due to activities undertaken in preparation for the Phase 3 study, including drug product and packaging, in the three months ended September 30, 2025.

General and administrative expenses

General and administrative expenses decreased by \$0.2 million, from \$6.2 million in the three months ended September 30, 2024 to \$6.0 million in the three months ended September 30, 2025. The decrease was primarily due to lower professional fees.

General and administrative expenses also includes \$0.8 million in the three months ended September 30, 2025 of pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe, if approved, including those to support pricing and reimbursement by HTA authorities and payor decision-makers in Europe.

Other income

Other income of \$0.3 million for the nine months ended September 30, 2025 comprised amounts received from āshibio in connection with the out-licensing of vantiactumab, which was acquired in connection with the merger between the Company and Mereo BioPharma 5, Inc.

Interest income and expense

Interest income decreased by \$0.5 million, from \$1.0 million in the three months ended September 30, 2024 to \$0.5 million in the three months ended September 30, 2025, principally due to a combination of lower interest rates earned and lower average cash and cash equivalents balances in the three months ended September 30, 2025 compared to the three months ended September 30, 2024. These lower balances were the result of having received the net proceeds of \$46.2 million from the underwritten registered direct offering in June 2024.

Interest expense decreased by \$0.3 million, from \$0.4 million in the three months ended September 30, 2024 to less than \$0.1 million in the three months ended September 30, 2025. The decrease was principally due to the conversion of convertible loan notes in February 2025, following which the Company had no significant remaining interest-bearing liabilities.

Changes in the fair value of warrants

The total change in fair value of warrants in the three months ended September 30, 2025 was an unrealized gain of \$0.2 million, compared to an unrealized loss of \$0.1 million in the three months ended September 30, 2024. The unrealized gain in the three months ended September 30, 2025 was primarily due to the impact of decreases in the price of the Company's ADSs on the value of the warrant liabilities, while the unrealized loss in the three months ended September 30, 2024 was primarily due to increases in the price of ADSs.

Foreign currency transaction gain/(loss), net

The net foreign exchange gain for the three months ended September 30, 2025 was \$1.9 million, compared to a loss of \$6.4 million for the three months ended September 30, 2024. This change primarily reflects the impact of a strengthening in the value of U.S. dollars when translating U.S. dollar balances into our functional currency of pound sterling in the three months ended September 30, 2025, compared to a weakening of U.S. dollars in the three months ended September 30, 2024.

Benefit from research and development tax credit

The benefit from research and development tax credit increased by \$0.2 million, from \$0.2 million in the three months ended September 30, 2024 to \$0.4 million in the three months ended September 30, 2025. This increase reflects a higher level of qualifying expenditure in the three months ended September 30, 2025. The income tax benefit represents eligible cash rebates paid or receivable from the tax authorities in the jurisdictions within which the Company operates for eligible types of research and development activities and associated expenditure.

Other comprehensive income – Foreign currency translation adjustments

The foreign currency translation adjustment for the three months ended September 30, 2025 was a loss of \$2.3 million, compared to a gain of \$7.2 million in the three months ended September 30, 2024. This change primarily reflects the impact of a strengthening in the value of U.S. dollars when translating pound sterling functional currency balances into our presentational

currency of U.S. dollars in the three months ended September 30, 2025, compared to a weakening of U.S. dollars in the three months ended September 30, 2024.

Comparison of nine months ended September 30, 2025 and 2024

The following table sets forth Mereo's results of operations for the nine months ended September 30, 2025 and 2024.

	Nine months ended September 30,		Change (\$'000)
	2025 (\$'000)	2024 (\$'000)	
Revenue	\$ 500	\$ —	500
Operating expenses			
Cost of revenue	(133)	—	(133)
Research and development	(13,573)	(12,109)	(1,464)
General and administrative	(18,811)	(19,980)	1,169
Other income	300	—	300
Loss from operations	(31,717)	(32,089)	372
Other income/(expenses)			
Interest income	1,752	2,160	(408)
Interest expense	(232)	(995)	763
Changes in the fair value of warrants	511	(576)	1,087
Foreign currency transaction loss, net	(6,218)	(5,780)	(438)
Benefit from research and development tax credit	1,377	1,073	304
Net loss before income tax	(34,527)	(36,207)	1,680
Income tax benefit	—	—	—
Net loss	\$ (34,527)	\$ (36,207)	1,680
Other comprehensive income – Foreign currency translation adjustments, net of tax	7,939	6,381	1,558
Total comprehensive loss	\$ (26,588)	\$ (29,826)	3,238

Revenue

Revenue of \$0.5 million for the nine months ended September 30, 2025 comprised a one-time milestone payment of \$0.5 million resulting from the achievement of a clinical milestone on leflutrozoled received from ReproNovo pursuant to the ReproNovo Licensing Agreement. No revenue was recognized for the nine months ended September 30, 2024.

Cost of revenue

Cost of revenue for the nine months ended September 30, 2025 was \$0.1 million and represents amounts paid pursuant to the 2015 asset purchase agreement with Novartis for leflutrozoled, under which the Company pays a percentage of proceeds resulting from milestone revenue received, subject to certain deductions and other amounts. No cost of revenue was recognized for the nine months ended September 30, 2024.

R&D expenses

The following table sets forth our R&D expenses by product development program for the nine months ended September 30, 2025 and 2024.

	Nine months ended		
	September 30,		
	2025	2024	Change
	(\$'000)	(\$'000)	(\$'000)
Setrusumab (BPS-804/UX143)	\$ 8,225	\$ 3,798	4,427
Alvelestat (MPH-966)	4,450	6,721	(2,271)
Etigilimab (MPH-313)	660	1,228	(568)
Other	238	362	(124)
Total R&D expenses	\$ 13,573	\$ 12,109	1,464

Total R&D expenses increased by \$1.5 million, from \$12.1 million in the nine months ended September 30, 2024 to \$13.6 million in the nine months ended September 30, 2025.

The increase was primarily due to an increase of \$4.4 million in R&D expenses for setrusumab, partially offset by decreases of \$2.3 million and \$0.6 million in R&D expenses for alvelestat and etigilimab, respectively.

The increase in program expenses for setrusumab was primarily driven by amounts due under the manufacturing and supply agreement with our partner, Ultragenyx, as well as ongoing activities related to real-world evidence programs and medical affairs activities in Europe. This is in addition to costs we incur in relation to our collaboration with Ultragenyx, who fund the global development of the program, including input into development, regulatory and manufacturing plans.

The decrease in program expenses for alvelestat was primarily due to the completion of activities undertaken in preparation for the Phase 3 study, including drug formulation and manufacturing, in the nine months ended September 30, 2024.

General and administrative expenses

General and administrative expenses decreased by \$1.2 million, from \$20.0 million in the nine months ended September 30, 2024 to \$18.8 million in the nine months ended September 30, 2025. The decrease was primarily due to lower professional fees.

General and administrative expenses also includes \$3.2 million in the nine months ended September 30, 2025 of pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe, if approved, including those to support pricing and reimbursement by HTA authorities and payor decision-makers in Europe.

Other income

Other income of \$0.3 million for the nine months ended September 30, 2025 comprised amounts received from āshibio in connection with the out-licensing of vantictumab, which was acquired in connection with the merger between the Company and Mereo BioPharma 5, Inc.

Interest income and expense

Interest income decreased by \$0.4 million, from \$2.2 million in the nine months ended September 30, 2024 to \$1.8 million in the nine months ended September 30, 2025, principally due to a combination of lower interest rates earned and lower average cash and cash equivalents balances in the three months ended September 30, 2025 compared to the three months ended September 30, 2024. These lower balances were the result of having received the net proceeds of \$46.2 million from the underwritten registered direct offering in June 2024.

Interest expense decreased by \$0.8 million, from \$1.0 million in the nine months ended September 30, 2024 to \$0.2 million in the nine months ended September 30, 2025. The decrease was principally due to the conversion of convertible loan notes in February 2025, following which the Company had no significant remaining interest-bearing liabilities.

Changes in the fair value of warrants

The total change in fair value of warrants in the nine months ended September 30, 2025 was an unrealized gain of \$0.5 million, compared to an unrealized loss of \$0.6 million in the nine months ended September 30, 2024. The unrealized gain in the nine months ended September 30, 2025 was primarily due to the impact of decreases in the price of the Company's ADSs on the value of the warrant liabilities, while the unrealized loss in the nine months ended September 30, 2024 was primarily due to increases in the price of ADSs.

Foreign currency transaction loss

The net foreign exchange loss for the nine months ended September 30, 2025 was \$6.2 million, compared to a loss of \$5.8 million for the nine months ended September 30, 2024. This change primarily reflects the impact of a greater weakening in the value of U.S. dollars when translating U.S. dollar balances into our functional currency of pound sterling in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.

Benefit from research and development tax credit

The benefit from research and development tax credit increased by \$0.3 million, from \$1.1 million in the nine months ended September 30, 2024 to \$1.4 million in the nine months ended September 30, 2025. This increase reflects a higher level of qualifying expenditure in the nine months ended September 30, 2025. The income tax benefit represents eligible cash rebates paid or receivable from the tax authorities in the jurisdictions within which the Company operates for eligible types of research and development activities and associated expenditure.

Other comprehensive income – Foreign currency translation adjustments

The foreign currency translation adjustment for the nine months ended September 30, 2025 was a gain of \$7.9 million, compared to a gain of \$6.4 million in the nine months ended September 30, 2024. This change primarily reflects the impact of a greater weakening in the value of U.S. dollars when translating pound sterling functional currency balances into our presentational currency of U.S. dollars in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.

Liquidity and Capital Resources

Overview

Under the current business plan and cash flow forecasts, and in consideration of our ongoing research and development efforts and our general corporate funding requirements, we anticipate that our current on-hand cash resources will extend into 2027. However, we will need additional external funding to complete our development plans and potentially commercialize selected rare disease products. We plan to fund our operations through cash on hand and a combination of non-dilutive funding sources, public or private equity or debt financing or other sources.

We do not currently have any approved product candidates and as a result, have not generated any revenue from product sales. As a result, to date, we have financed our operations primarily through the issuances of our equity securities, convertible debt and warrants. These offerings have raised approximately \$259.0 million, including through the \$50.0 million underwritten registered direct offering in June 2024 and the \$12.0 million “at-the-market” offering pursuant to our Open Market Sale Agreement with Jefferies LLC in July 2023 (all amounts are gross proceeds before fees and discounts).

We have also received payments under various license and collaboration agreements, including payments of:

- \$50.0 million under the license and collaboration agreement with Ultragenyx for setrusumab in 2021 and a further milestone payment of \$9.0 million in 2023;
- \$4.0 million under the license and collaboration agreement with Feng Biosciences (formerly OncXerna) for navicixizumab in 2020 and a further milestone payment of \$2.0 million in 2022; and
- \$1.0 million under the global license agreement with ReproNovo for leflutrolole in December 2023 and a further milestone payment of \$0.5 million in 2025.

Contractual Obligations

As further described in our 2024 Annual Report, under “Item 1. Business—Material Agreements—Novartis Agreements” (as updated in Note 16 to the condensed consolidated financial statements included in this Quarterly Report) and “Item 1. Business—Material Agreements—Licensing Agreement with AstraZeneca,” under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on potential future commercial sales. The amount, timing, and likelihood of such payments are not known and will remain uncertain for the foreseeable future.

In addition, we enter into contracts in the ordinary course of business with CROs, CMOs, and other vendors, including Ultragenyx for the manufacture of setrusumab as described in our 2024 Annual Report in “Item 1. Business—Material Agreements—Agreements with Ultragenyx for Setrusumab”, to assist in the performance of its research and development activities and other services and products for operating purposes. The contracts with CROs generally provide for termination on notice, and therefore are cancelable contracts. We have manufacturing commitments with CMOs of \$0.1 million and \$0.5 million as of September 30, 2025 and December 31, 2024, respectively.

Cash Flows

Comparison of the nine months ended September 30, 2025 and 2024

The table below summarizes our cash flows (used in)/provided by operating, investing and financing activities for the nine months ended September 30, 2025 and 2024.

	Nine Months Ended	
	September 30,	
	2025	2024
	(\$'000)	(\$'000)
Net cash used in operating activities	\$ (23,289)	\$ (23,414)
Net cash used in investing activities	(20)	(699)
Net cash provided by financing activities	288	46,187
Effect of exchange rate changes	1,917	1,027
(Decrease)/increase in cash and cash equivalents	<u>\$ (21,104)</u>	<u>\$ 23,101</u>

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2025 was \$23.3 million, a decrease of \$0.1 million from \$23.4 million in the nine months ended September 30, 2024. This decrease is principally due to:

- a) receipt of \$3.3 million in R&D tax credits in the nine months ended September 30, 2025; and
- b) receipt of a \$0.5 million one-time milestone payment in the nine months ended September 30, 2025 for the achievement of a clinical milestone on leflutroazole in the six months ended June 30, 2025, net of \$0.1 million paid to Novartis.

These decreases were offset by receipt of \$2.0 million from a claim on our Directors and Officers insurance policy to reimburse us for certain legal and professional costs incurred in prior years in the nine months ended September 30, 2024 with no similar amounts recognized in the nine months ended September 30, 2025 and higher net cash operating payments of approximately \$1.6 million.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2025 was less than \$0.1 million, a decrease of \$0.7 million from \$0.7 million in the nine months ended September 30, 2024. The decrease is principally due to lower payments to acquire intangible assets and proceeds from out-licensing of vantictumab in the nine months ended September 30, 2025.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2025 was \$0.3 million, a decrease of \$45.9 million from \$46.2 million in the nine months ended September 30, 2024. The decrease primarily represents the net proceeds of \$46.2 million from the underwritten registered direct offering in the nine months ended September 30, 2024 with no similar financing activities in the nine months ended September 30, 2025.

Operating and Capital Expenditure Requirements

As of September 30, 2025, we had an accumulated deficit of \$493.7 million. We expect to continue to report significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval of our product candidates and any future product candidates we develop.

We expect to continue to incur expenses in connection with our ongoing development activities related to our product candidates, our outsourced manufacturing activities and other associated costs including the management of our intellectual property portfolio. We also expect to continue to incur costs associated with operating as a U.S. public company listed on Nasdaq and as a domestic registrant.

These costs will increase further if we:

- seek to develop additional product candidates;
- seek regulatory approvals for any of our product candidates that successfully complete clinical trials;
- potentially establish a sales, marketing, and distribution infrastructure and scale-up manufacturing capabilities to commercialize or co-commercialize any product candidates for which we may obtain regulatory approval and chose to commercialize directly;
- expand our intellectual property portfolio;
- add further clinical, scientific, operational, financial, legal and management information systems, and personnel, including personnel to support our development, potential commercialization and to support our operations as a U.S. public company listed on Nasdaq; or
- experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues, manufacturing issues, or other regulatory challenges.

We expect that our existing cash and cash equivalents will enable us to fund our currently committed clinical trials, operating expenses and capital expenditure requirements into 2027. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:

- the costs for our activities related to our ongoing collaboration with Ultragenyx for setrusumab for the treatment of children and adults with OI, including the costs for our preparation for the potential commercialization of setrusumab, if approved, in Europe and the U.K; and potential future costs for the alvelestat program in AATD;
- the costs and timing of manufacturing clinical or commercial supplies of our product candidates;
- the costs, timing, and outcome of regulatory review of our product candidates, including post-marketing studies that could be required by regulatory authorities;
- the costs, timing, and outcome of potential future commercialization activities, including manufacturing, marketing, sales, life cycle management and distribution, for our product candidates that we commercialize directly;
- the timing and amount of revenue, if any, received from commercial sales of our product candidates;
- the costs and timing of preparing, filing, and prosecuting patent applications; maintaining and enforcing our intellectual property rights; and defending any intellectual property-related claims, including any claims by third parties that we are infringing, misappropriating or otherwise violating their intellectual property rights;
- the sales price and availability of adequate third-party coverage and reimbursement for our product candidates;
- the effect of competitors and market developments;
- the performance of our collaborators and partners under the existing agreements on setrusumab, vantictumab, leflutroazole and navicixizumab;

- the extent to which we are able to acquire new product candidates or enter into licensing or collaboration arrangements for our product candidates, although we currently have no commitments or agreements to complete any such transactions;
- milestone payments under the Amended AstraZeneca Agreements; and
- tax liabilities or other assessments and our ability to claim R&D tax credits or other reliefs.

Our revenues, if any, will be derived from development milestones or sales of any product candidates that we are able to successfully develop, receive regulatory approval for, and commercialize in future years. In the meantime, we will need to obtain substantial additional funds to achieve our business objective.

Adequate additional funds may not be available to us on acceptable terms, or at all. If we raised additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.

Any future debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interests.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, shareholders' ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. If we are unable to raise additional funds through partnerships, debt or equity financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Critical Accounting Estimates

Our unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our accounting estimates based on historical experience and on various other assumptions that we believe are reasonable under the circumstances. The actual impact on our financial performance could differ from these estimates under different assumptions or conditions.

An accounting estimate is considered critical if both (i) the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment involved, and (ii) the impact within a reasonable range of outcomes of the estimates and assumptions is material to our unaudited condensed consolidated financial statements. We believe that there are no estimates and assumptions made in our unaudited condensed consolidated financial statements that rise to this level. Our significant accounting policies are described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates" in our 2024 Annual Report, which was filed with the SEC on March 26, 2025. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected. There have been no significant changes to our critical accounting estimates from those described in our 2024 Annual Report.

Recent accounting pronouncements

There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance other than those previously included in the 2024 Annual Report that are of significance or potential significance to the Company. The Company is continuing to evaluate the impact of the recently issued pronouncements that are effective in future periods and were discussed in its 2024 Annual Report.

Safe Harbor

See the section titled "Information Regarding Forward-Looking Statements" at the beginning of this Quarterly Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”) as of September 30, 2025.

Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at September 30, 2025.

Changes in Internal Control over Financial Reporting.

No changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) occurred during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

As of September 30, 2025, we were not a party to any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in the Company's 2024 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three-month period ended September 30, 2025, none of our directors or officers adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as such terms are defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

The following exhibits are either provided with this Quarterly Report on Form 10-Q or are incorporated herein by reference:

Exhibit Number	Description of Exhibit
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104	The cover page for the Company's Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on November 10, 2025.

MEREO BIOPHARMA GROUP PLC

Date: November 10, 2025

/s/ Denise Scots-Knight

Denise Scots-Knight
Chief Executive Officer

Date: November 10, 2025

/s/ Christine Fox

Christine Fox
Chief Financial Officer

**Certification by the Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Denise Scots-Knight, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mereo BioPharma Group plc (the “Company”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the quarterly report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit and risk committee of the Company’s board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 10, 2025

/s/ Denise Scots-Knight

Name: Denise Scots-Knight
Title: Chief Executive Officer

**Certification by the Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Christine Fox, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mereo BioPharma Group plc (the “Company”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the quarterly report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit and risk committee of the Company’s board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: November 10, 2025

/s/ Christine Fox

Name:	Christine Fox
Title:	Chief Financial Officer

**Certification by the Chief Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the quarterly report of Mereo BioPharma Group plc (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Denise Scots-Knight, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2025

By: /s/ Denise Scots-Knight
Name: Denise Scots-Knight
Title: Chief Executive Officer

**Certification by the Chief Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the quarterly report of Mereo BioPharma Group plc (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christine Fox, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 10, 2025

By: /s/ Christine Fox
Name: Christine Fox
Title: Chief Financial Officer
